louisbrulenaudet/clinical-trials huggingface dataset:
Clinical trial NCT04741113: The Effect of an Education Module to Reduce Weight Bias Among Healthcare Professionals in a Private Hospital Setting
Official title: The Effect of an Education Module to Reduce Weight Bias Among Healthcare Professionals in a Private Hospital Setting
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: NA
Conditions: Obese, Stigma
Lead sponsor: Assuta Medical Center
Sponsor class: OTHER
First posted: 2021-02-05
Enrollment: 506
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: yes
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: OTHER

Brief summary: Although scientific bodies have recognized obesity as a disease, obese people are often stigmatized, facing discrimination, and accusations that they are responsible to their condition due to their lack of willpower by healthcare professionals. However, experimental research to reduce weight bias among healthcare professionals is lacking, and published studies to date are methodologically flawed, including lack of randomization, lack of control group and small sample size.

The study is designed to evaluate the effect of a comprehensive online education module on knowledge about obesity and weight bias in a convenience sample in a private hospital setting.

This is an interventional study conducted among all Assuta Medical Centers healthcare employees including physicians, bariatric surgeons, nurses, dietitians, social workers, physiotherapists, pharmacists, imaging department technicians, laboratory workers, patient services assistants and medical secretariats. Participants who will confirm their consent to participate in the study, will be randomized into two arms: intervention vs. control (with no intervention). The study intervention will include an online 15-minute educational module which will be based on relevant literature and expert opinion and will include four sections: a) Knowledge about obesity; b) Weight bias definition and impact; c) Strategies to reduce weight bias; d) A short quiz. At baseline, one week and one-month post intervention, both groups will respond to an anonymous on-line survey on knowledge about obesity and weight stigma. Moreover, data on demographic parameters of study participants will be collected.


Eligibility criteria: Inclusion Criteria:

* All Assuta Medical Centers healthcare employees will be recruited to the study

Exclusion Criteria:

-

Primary outcomes:
measure: Weight stigma
timeFrame: Change from Baseline at 1 month post intervantion
Secondary outcomes:
measure: Knowledge about obesity
timeFrame: Change from Baseline at 1 month post intervantion
Other outcomes:
Locations:
city: Tel Aviv
country: Israel
facility: Assuta Medical Center
Study officials:
References:
citation: Sherf-Dagan S, Kessler Y, Mardy-Tilbor L, Raziel A, Sakran N, Boaz M, Kaufman-Shriqui V. The Effect of an Education Module to Reduce Weight Bias among Medical Centers Employees: A Randomized Controlled Trial. Obes Facts. 2022;15(3):384-394. doi: 10.1159/000521856. Epub 2022 Jan 21.
Clinical trial NCT00830713: Vitiligo Skin Transplantation
Official title: Safety and Efficacy of Melanocyte-keratinocyte Transplantation in the Treatment of Vitiligo
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: PHASE3
Conditions: Vitiligo
Keywords: vitiligo
skin transplantation
non-cultured
melanocyte
surgery
Lead sponsor: Henry Ford Health System
Sponsor class: OTHER
First posted: 2009-01-28
Enrollment: 40
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: NA
Intervention model: SINGLE_GROUP
Primary purpose: TREATMENT

Brief summary: In vitiligo, the melanocytes are lost from the skin in certain areas. One treatment for vitiligo takes the melanocytes from areas of normal skin and places them on areas of that same person's body which have lost their color. This is called the melanocyte-keratinocyte transplantation procedure (MKTP). This procedure has been used successfully in over 3000 cases in India and Saudi Arabia. The purpose of this study is to see if it is effective when performed at the investigators' institution.


Eligibility criteria: Inclusion Criteria:

1. Be at least 18 years old
2. Have a diagnosis of vitiligo with no news lesions or growth of old lesions in the past 6 months
3. Be able to understand the requirements of the study, the risks involved, and be able to sign the informed consent form
4. Agree to follow and undergo all study-related procedures

Exclusion Criteria:

1. Female patients who are breastfeeding, pregnant, or planning to become pregnant
2. Patients with a history of developing vitiligo or keloids at sites of trauma
3. Patients self-reported as having HIV or Hepatitis C
4. Patients self-reported as having uncontrolled Diabetes Mellitus
5. The investigator feels the patient should not participate in the study for any reason

Primary outcomes:
measure: effectiveness of MKTP in treating vitiligo
timeFrame: 6 months
Secondary outcomes:
measure: safety of MKTP in treating vitiligo
timeFrame: 6 months
Other outcomes:
Locations:
city: Detroit
country: United States
facility: Henry Ford Medical Center, New Center One
state: Michigan
Study officials:
affiliation: Henry Ford Health Systems Dermatology Department
name: Iltefat H Hamzavi, MD
role: PRINCIPAL_INVESTIGATOR
References:
citation: Mulekar SV. Long-term follow-up study of segmental and focal vitiligo treated by autologous, noncultured melanocyte-keratinocyte cell transplantation. Arch Dermatol. 2004 Oct;140(10):1211-5. doi: 10.1001/archderm.140.10.1211.
citation: Mulekar SV. Long-term follow-up study of 142 patients with vitiligo vulgaris treated by autologous, non-cultured melanocyte-keratinocyte cell transplantation. Int J Dermatol. 2005 Oct;44(10):841-5. doi: 10.1111/j.1365-4632.2005.02226.x.
Clinical trial NCT06796413: Loop Resection or Cold-cup Biopsy? A Study Comparing the Accuracy of Muscle Samples During Bladder Tumor Surgery
Official title: Loop Resection or Cold-cup Biopsy? A Prospective Randomized Study Evaluating the Accuracy of Detrusor Muscle Representation During Transurethral Resection of Bladder Tumors
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: NA
Conditions: Bladder Cancer
Bladder Cancer Stage I
TURBT
Keywords: Bladder Cancer
Detrusor Muscle Sampling
Detrusor Muscle Representation
Loop Resection
Cold-Cup Biopsy
Artifacts
Lead sponsor: University of Stellenbosch
Sponsor class: OTHER
First posted: 2025-01-28
Enrollment: 120
Sex: ALL
Standard ages: CHILD
ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: DIAGNOSTIC

Brief summary: In this report the investigators compared two deep muscle sampling methods (Loop resection and Cold-Cup Biopsy) during endoscopic resection of bladder tumors for patients with suspected bladder cancer in Tygerberg hospital. The investigators found that both sampling methods are equal effective with regards to muscle representation, regardless of surgeon experience. An important finding is that Loop Resection produced less tissue artefacts in the deep muscle specimen for the more experienced surgeons, while there was no difference for less experienced surgeons. The investigators thus conclude that - from a practical point of view - Loop Resection should be the deep muscle sampling method of choice.


Eligibility criteria: Inclusion Criteria:

* • All patients requiring cystoscopy plus loop resection of bladder tumor.

Exclusion Criteria:

* • Patients who underwent cystoscopy and no loop resection

  * Patients who underwent cystoscopy and only cold-cup biopsy

Primary outcomes:
measure: Detrusor Muscle Representation
timeFrame: From enrollment to the end of treatment at 2-4 weeks when histology results are available
Secondary outcomes:
Other outcomes:
Locations:
city: Cape Town
country: South Africa
facility: Stellenbosch University - Faculty of Health Sciences - Department of Urology
state: Western Cape
Study officials:
affiliation: University of Stellenbosch
name: Eduan Delport, MB, ChB
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT02306213: Effect of Hydroxyethylstarch 6% 130/0.4 Administration on Renal Function After Cardiac Surgery
Official title: Effect of Hydroxyethylstarch 6% 130/0.4 Administration on Renal Function After Cardiac Surgery
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: NA
Conditions: Kidney Function Tests
Lead sponsor: Cliniques universitaires Saint-Luc- Université Catholique de Louvain
Sponsor class: OTHER
First posted: 2014-12-03
Enrollment: 1564
Sex: ALL
Minimum age (years): 18
Maximum age (years): 90
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: NON_RANDOMIZED
Intervention model: PARALLEL
Primary purpose: TREATMENT

Brief summary: Recent studies have shown an increased incidence of renal replacement therapy after the use of Hydroxyethylstarchs (HES) in patients admitted in the intensive care unit. However, studies showing detrimental effects of HES have been conducted in mostly non-surgical subjects. There are very few studies analyzing the effects of HES on renal function after cardiac surgery, a population already at risk of renal dysfunction.


Eligibility criteria: Inclusion Criteria:

* All patients undergoing cardiac surgery

Exclusion Criteria:

* Heart transplantation
* Ventricular assist devices
* Patients requiring extracorporeal life support before or after cardiac surgery
* Patients revised for bleeding and/or tamponnade presenting with hemodynamic instability
* Patients in whom the administered volume therapy was not completely available
* Subjects who required renal replacement therapy before surgery
* Trauma patients who were put on cardiopulmonary bypass
* Patients who died intra-operatively or soon after arrival in the intensive care unit in whom no postoperative creatinine measurements were available

Primary outcomes:
measure: Renal dysfunction based on RIFLE (Risk; Injury; Failure; Loss; End-stage) criteria.
timeFrame: Up to 45 days
Secondary outcomes:
measure: Mortality
timeFrame: Up to 45 days
Other outcomes:
Locations:
Study officials:
References:
Clinical trial NCT02491736: Ketoprofen Gel vs Placebo in Children With Ankle Sprain
Official title: Ketoprofen Gel vs Placebo in Children Presented With Ankle Sprain to the Emergency Department: A Randomised Controlled Trial
Study type: INTERVENTIONAL
Overall status: UNKNOWN
Phase: PHASE4
Conditions: Ankle Sprain
Lead sponsor: Akdeniz University
Sponsor class: OTHER
First posted: 2015-07-08
Enrollment: 100
Sex: ALL
Minimum age (years): 8
Maximum age (years): 18
Standard ages: CHILD
ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: TREATMENT

Brief summary: The aim of this study is to analyse the effect of ketoprofen gel in children presented with ankle sprain to the emergency department.

Detailed description: Ankle sprains may be associated with soft tissue injuries and fractures. Although diagnostic modalities are important, alleviation of pain is also a part of emergency department management. The aim of this study is to analyse the effect of ketoprofen gel in children presented with ankle sprain to the emergency department.

Eligibility criteria: Inclusion Criteria:

* Patients with ankle sprain
* Patients over 8 and lower than 18 years old

Exclusion Criteria:

* Ankle sprain more than 24 hours
* visual analogue scale score lower than 40mm
* Allergy to the study drug

Primary outcomes:
measure: Visual Analogue Scale
timeFrame: 30 minutes
Secondary outcomes:
measure: Adverse effects
timeFrame: 30 minutes
Other outcomes:
Locations:
city: Denizli
country: Turkey
facility: Pamukkale University
Study officials:
affiliation: Pamukkale University
name: Mustafa Serinken, MD
role: STUDY_CHAIR
References:
Clinical trial NCT06590636: Impact of Expressive Touching During Embryo Transfer
Official title: Impact of Expressive Touching During Embryo Transfer on the Anxiety and Pregnancy Rate of Women Undergoing in Vitro Fertilization
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: NA
Conditions: IVF-ET
Keywords: Embryo
Expressive Touching
Women
Pregnancy
Anxiety
In Vitro Fertilization
Lead sponsor: TC Erciyes University
Sponsor class: OTHER
First posted: 2024-09-19
Enrollment: 64
Sex: FEMALE
Minimum age (years): 25
Maximum age (years): 35
Standard ages: ADULT
Accepts healthy volunteers: yes
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: SUPPORTIVE_CARE

Brief summary: Infertile individuals report psychiatric symptoms and that their levels of anxiety and depression are significantly higher than in fertile controls .Thus,this study aimed to determine the effect of expressive touching during embryo transfer on the anxiety and pregnancy rate.


Eligibility criteria: Inclusion Criteria:

* Having a diagnosis of primary infertility,
* Being over the age of 25 and under the age of 35
* Able to read and write Arabic,
* Women who will be applied assisted reproductive techniques such as IVF- ICSI-ET,
* Women with the same drugs and protocols used in IVF treatment was included in the study.

Exclusion Criteria:

* Women who have problems in understanding and perception,
* Having a diagnosis of secondary infertility wasn\&amp;#39;t included in the study

Primary outcomes:
measure: The State-Trait Anxiety Inventory Scale
timeFrame: Anxiety levels in women were measured using the State-Trait Anxiety Inventory (STAI) both before and after the embryo transfer procedure. The assessments were conducted within 5 to 10 minutes of each other to capture the immediate impact of the procedure
Secondary outcomes:
Other outcomes:
Locations:
city: Gaza
country: Palestinian Territory, occupied
facility: Albasma a private IVF center
Study officials:
References:
Clinical trial NCT01046136: Mucinex Exploratory Cold Study
Official title: Double Blind, Randomized, Placebo Controlled Study of Mucinex® for the Treatment of Symptoms of an Acute Respiratory Tract Infection When Two 600 mg Tablets Are Given Every 12 Hours for 7 Days
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: PHASE2
Conditions: Common Cold
Keywords: common cold
Lead sponsor: Reckitt Benckiser LLC
Sponsor class: INDUSTRY
First posted: 2010-01-11
Enrollment: 378
Sex: ALL
Minimum age (years): 12
Standard ages: CHILD
ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: TREATMENT

Brief summary: This is an exploratory, multicenter, randomized, blinded, placebo-controlled study of Mucinex in patients with colds. Patients will receive 7 days of treatment with either Mucinex or placebo. The study will assess the effects of Mucinex on sputum and cold symptoms.


Eligibility criteria: Inclusion Criteria:

* common cold symptoms
* meet symptom severity
* females of child-bearing potential must have negative pregnancy test and use effective birth control

Exclusion Criteria:

* chronic respiratory conditions
* significant heart, kidney, liver, or lung disease, uncontrolled hypertension or diabetes, cystic fibrosis, thyroid disorder
* pregnant or lactating
* known malignancy
* participation in any other clinical trial within 30 days of baseline
* related to another enrolled patient or persons involved directly or indirectly with the conduct of this study

Primary outcomes:
measure: Investigator's End of Study Assessment of Treatment
timeFrame: 7 days
measure: Mean Change From Baseline in a 6 Point Severity Scale (0 = None, 1 = Very Mild, 2 = Mild or Slight, 3 = Moderate, 4 = Severe or 5 = As Bad as it Can be) for Cough.
timeFrame: Baseline and Day 4
Secondary outcomes:
measure: Number of Patients With Adverse Events
timeFrame: 7 days
Other outcomes:
Locations:
city: Bellevue
country: United States
facility: Pioneer Clinical Research
state: Nebraska
Study officials:
References:
citation: Hoffer-Schaefer A, Rozycki HJ, Yopp MA, Rubin BK. Guaifenesin has no effect on sputum volume or sputum properties in adolescents and adults with acute respiratory tract infections. Respir Care. 2014 May;59(5):631-6. doi: 10.4187/respcare.02640. Epub 2013 Sep 3.
citation: Albrecht H, Vernon M, Solomon G. Patient-reported outcomes to assess the efficacy of extended-release guaifenesin for the treatment of acute respiratory tract infection symptoms. Respir Res. 2012 Dec 27;13(1):118. doi: 10.1186/1465-9921-13-118.
Clinical trial NCT00002236: A Study to Find the Best Dosing Schedule for Delavirdine, Zidovudine, and Indinavir in HIV-Positive Patients
Official title: An Open-Label, Parallel Group, Pilot Study of Safety, Tolerance, Pharmacokinetics and Pharmacodynamics of BID and TID Regimens of Delavirdine Mesylate, Zidovudine, and Indinavir Sulfate in HIV-1 Infected Individuals
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: NA
Conditions: HIV Infections
Keywords: Drug Therapy, Combination
Zidovudine
Drug Administration Schedule
HIV Protease Inhibitors
CD4 Lymphocyte Count
Indinavir
Delavirdine
Reverse Transcriptase Inhibitors
Anti-HIV Agents
Viral Load
Lead sponsor: NIH AIDS Clinical Trials Information Service
Sponsor class: INDUSTRY
First posted: 2001-08-31
Enrollment: 32
Sex: ALL
Minimum age (years): 14
Standard ages: CHILD
ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Primary purpose: TREATMENT

Brief summary: The purpose of this study is to see whether it is better to take delavirdine (DLV) plus indinavir (IDV) plus zidovudine (ZDV) twice a day or three times a day.

Detailed description: Patients are divided into 2 treatment groups; the groups are balanced with respect to viral load. Group A receives ZDV, DLV, and IDV 3 times daily. Group B receives ZDV, DLV, and IDV 2 times daily. Patients are evaluated for changes from baseline in viral load and CD4 cell count.

Eligibility criteria: Inclusion Criteria

You may be eligible for this study if you:

* Are HIV-positive.
* Have a viral load (level of HIV in the blood) of at least 20,000 copies/ml.
* Have a CD4 cell count of at least 50 cells/mm3.
* Are at least 14 years old (consent of parent or guardian is required if under 18).

Exclusion Criteria

You will not be eligible for this study if you:

* Have ever taken an anti-HIV drug other than ZDV.
* Have taken ZDV for more than 1 month.

Primary outcomes:
Secondary outcomes:
Other outcomes:
Locations:
city: Los Angeles
country: United States
facility: AIDS Healthcare Foundation
state: California
city: San Francisco
country: United States
facility: UCSF AIDS Research Institute
state: California
city: New York
country: United States
facility: Saint Luke's - Roosevelt Hosp Ctr
state: New York
city: Pittsburgh
country: United States
facility: Anderson Clinical Research
state: Pennsylvania
city: Memphis
country: United States
facility: Univ of Tennessee / Div of Infect Dis / Dept of Med
state: Tennessee
city: Annandale
country: United States
facility: Infectious Disease Physicians Inc
state: Virginia
Study officials:
References:
Clinical trial NCT05971836: The Molecular Basis of Inherited Reproductive Disorders
Official title: The Molecular Basis of Inherited Reproductive Disorders
Study type: OBSERVATIONAL
Overall status: RECRUITING
Conditions: Hypogonadotropic Hypogonadism
Reproductive Disorder
Kallmann Syndrome
Delayed Puberty
Keywords: Hypogonadotropic hypogonadism
Reproductive disorders
Kallmann syndrome
Kisspeptin
Delayed Puberty
Lead sponsor: Massachusetts General Hospital
Sponsor class: OTHER
First posted: 2023-08-02
Enrollment: 600
Sex: ALL
Minimum age (years): 1
Standard ages: CHILD
ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Observational model: COHORT
Time perspective: PROSPECTIVE
Sampling method: NON_PROBABILITY_SAMPLE
Study population: Individuals with reproductive disorders and their affected and unaffected family members

Brief summary: The goal of this study is to learn more about the genes that control puberty and reproduction in humans.

Detailed description: All study subjects will undergo the same activities. Subjects will provide up to five tubes of blood for genetic analysis, complete a smell test, and answer questions about their health and family history.

Eligibility criteria: Participants must belong to one of the following categories:

* Failure to go through a normal, age-appropriate, spontaneous puberty and low sex steroid levels in the setting of low/normal gonadotropins or,
* Abnormally early development of puberty or,
* Normal puberty with subsequent development of low gonadotropin levels or,
* Evidence of a reproductive disorder with high gonadotropin levels or,
* Pre-pubertal individuals with features suggestive of hypogonadotropic hypogonadism or,
* Affected and unaffected family members of individuals that fit criteria above

Primary outcomes:
measure: Genetic variation
timeFrame: Day 1
Secondary outcomes:
Other outcomes:
Locations:
city: Boston
country: United States
facility: Massachusetts General Hospital
state: Massachusetts
Study officials:
affiliation: Massachusetts General Hospital
name: Stephanie Seminara, MD
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT03587636: Liposome Bupivacaine Interscalene Total Shoulder
Official title: Prospective Randomized Controlled Trial Comparing Liposomal Bupivacaine to Bupivacaine Interscalene Blocks for Total Shoulder Arthroplasty Surgery; a Pilot Study
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: PHASE2
Conditions: Acute Pain
Lead sponsor: University of Minnesota
Sponsor class: OTHER
First posted: 2018-07-16
Enrollment: 77
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: yes
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: TREATMENT

Brief summary: This is a randomized prospective outcomes study comparing two groups of patients. One group will receive liposomal bupivacaine plus bupivacaine and the other will receive bupivacaine alone in interscalene blocks when undergoing total shoulder arthroplasty. The purpose of the study is to determine if LB plus bupivacaine provides superior pain control compared to bupivacaine alone when injected in an interscalene block for patients undergoing total shoulder arthroplasty surgery.

Detailed description: Liposomal bupivacaine (LB) is a long acting local anesthetic. It is liposome encapsulated bupivacaine which allows for prolonged release of bupivacaine over a 72-hour period. Bupivacaine is a medium acting local anesthetic which provides between 6 and 24 hours of analgesia when used in a peripheral nerve block. Both medications are standard of care for use in interscalene blocks here at the U of MN.

LB has not been adequately studied in peripheral nerve blocks and has yet to be studied for use in interscalene blocks for Total Shoulder Arthroplasty (TSA) patients. It has been studied in Rotator Cuff Repairs (RCR) surgery and showed superior analgesia compared to bupivacaine.

The purpose of the study is to determine if LB plus bupivacaine provides superior pain control compared to bupivacaine alone when injected in an interscalene block for patients undergoing total shoulder arthroplasty surgery.

Eligibility criteria: Inclusion Criteria:

* All adult patients aged greater than 18 years of age that are undergoing total or reverse total shoulder arthroplasty

Exclusion Criteria:

* Patients with allergy to local anesthetics, daily use of opioids for more than 3 weeks prior to surgery, patient refusal, patient with coagulopathy, non-english speaking patients, and those who do not have access to a telephone.

Primary outcomes:
measure: Total Opioid Use
timeFrame: From end of surgery through 72 hours after end of surgery
Secondary outcomes:
measure: Total Maximum Pain Scores f
timeFrame: time from end of surgery through 72 hours after end of surgery
Other outcomes:
Locations:
city: Minneapolis
country: United States
facility: University of Minnesota
state: Minnesota
Study officials:
affiliation: University of Minnesota
name: James Flaherty, MD
role: PRINCIPAL_INVESTIGATOR
References: